5 completed, 4 active not recruiting, 4 unknown, 1 enrolling by invitation. 7 Not applicable, 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 7 | Completed 4, Unknown 2, Active not recruiting 1 |
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Movember Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The PROSECCA Study, Answering New Questions in Prostate Cancer Prostate Cancer | Recruiting | University of Edinburgh | 15000 | 2024-07-01 | 2026-08-26 | |
| Prostate Cancer Awareness and Initiative for Screening in the European Union Risk-based screening algorithm - Prostate Cancer | Enrolling by invitation | European Association of Urology Research Foundation | 20000 | 2024-06-01 | 2025-08-15 | |
| "OnCall": Implementation Study of M-Health for Canadian Public Safety Personnel OnCall mobile health peer support app - Mental Health Issue, Mental Stress | Unknown | McMaster University | 210 | 2022-07-30 | 2022-06-22 | |
| A Web-based Peer Navigation Program for Men With Prostate Cancer Peer navigation, Active wait list control - Prostate Cancer | Not applicable | Completed | University Health Network, Toronto | 184 | 2022-05-13 | 2026-01-09 |
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy 177Lu-PSMA-617 - Prostatic Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 20 | 2020-08-06 | 2024-11-08 |
| In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy 177Lu-PSMA-617, Docetaxel - Metastatic Hormone Naive Prostate Cancer | Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 130 | 2020-04-21 | 2025-07-11 |
| A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer 177Lu-PSMA617, Cabazitaxel - Cancer of the Prostate, Metastatic Cancer | Phase 2 | Completed | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 201 | 2018-01-29 | 2022-06-13 |
| Comorbid Mental Disease and Heart Disease in Men Stepped-care model - Acute Coronary Syndrome, Depressive Disorder | Unknown | Universite de Moncton | 3000 | 2017-12-01 | 2017-11-28 | |
| INTERVAL - Intense Exercise Trial for Men With Metastatic Castrate-Resistant Prostate Cancer Intensive Exercise Intervention - Prostate Cancer | Not applicable | Unknown | Guy's and St Thomas' NHS Foundation Trust | 80 | 2017-09-01 | 2020-08-11 |
| Internet-Based Exercise and Diet Support in Prostate Cancer Survivors Written Information, Prescription, Technology - Cancer Survivor, Prostate Carcinoma | Not applicable | Completed | OHSU Knight Cancer Institute | 206 | 2017-08-01 | 2020-07-29 |
| The Effects of E-mental Health Program and Job Coaching on the Risk of Major Depression in Canadian Working Men e-mental health program, e-mental health program and job coaching, No intervention - Depression, Men | Not applicable | Completed | University of Calgary | 1133 | 2016-09-01 | 2019-05-17 |
| True NTH Sexual Recovery Intervention for Prostate Cancer Survivors and Their Partners website - Sexual Disfunction, Prostate Cancer | Not applicable | Completed | University of Michigan | 251 | 2016-03-01 | 2020-01-22 |
| INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4) High intensity aerobic and resistance training, Psychosocial support - Metastatic Prostate Cancer | Not applicable | Active not recruiting | Movember Foundation | 866 | 2016-01-01 | 2024-11-27 |
| An Intervention Study to Evaluate a Website Tailored to New Dads to Promote Mental Health Psychoeducational modules to prevent/reduce depression, Control Group - Mental Health in Expectant First-time Fathers | Not applicable | Unknown | McGill University | 72 | 2015-12-01 | 2021-03-02 |
| Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors paclitaxel, ifosfamide, cisplatin - Germ Cell Tumor, Teratoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 420 | 2015-08-06 | 2026-06-16 |
Prostatic Neoplasms (9) · Neoplasm Metastasis (3) · Stress Disorders, Post-Traumatic (2) · Acute Coronary Syndrome (1) · Anxiety Disorders (1) · Choriocarcinoma (1) · Depression (1) · Depressive Disorder (1) · Endodermal Sinus Tumor (1) · Germinoma (1) · Motor Activity (1) · Multiple Endocrine Neoplasia Type 1 (1) · Neoplasms (1) · Neoplasms, Germ Cell and Embryonal (1) · Nonseminomatous germ cell tumor (1)
Pluvicto (3) · Control Groups (2) · Biopsy (1) · Carboplatin (1) · Cisplatin (1) · Docetaxel (1) · Etoposide (1) · Granulocyte Colony-Stimulating Factor (1) · Ifosfamide (1) · Paclitaxel (1) · Prescriptions (1) · Psychiatric Rehabilitation (1) · Resistance Training (1) · Technology (1) · cabazitaxel (1)
Australia (5) · Canada (4) · United Kingdom (4) · United States (4) · Germany (2) · Ireland (2) · Netherlands (2) · Spain (2) · Belgium (1) · Denmark (1) · France (1) · Italy (1) · Lithuania (1) · Poland (1) · Switzerland (1)
Arun Azad, MBBS PhD FRACP (1) · Bill Nailon (1) · Daniela Wittmann, PhD (1) · Darren Feldman, MD (1) · Declan Murphy (1) · Duncan McLaren (1) · Fred Saad (1) · Hendrik Van Poppel, Prof (1) · Jackie Bender, PhD (1) · Jalila Jbilou, MD, PhD (1) · JianLi Wang (1) · John Violet (1) · Kerri Winters-Stone (1) · Michael Hofman, A/Prof (1) · Michael Hofman, MBBS(Hons),FRACP,FAANMS,FICIS (1)
PMID 27847352, PMID 28969611, PMID 29764892, PMID 30442638, PMID 30563754, PMID 31595044, PMID 33382378, PMID 33581798, PMID 34373282, PMID 36261050, PMID 36350899, PMID 37891072, PMID 38043558, PMID 38951803, PMID 39028926, PMID 39293461, PMID 39632499, PMID 40425844, PMID 41628931, PMID 42802883
U10CA180821 (1)